Key result
This editorial reviews the rationale for dual antiplatelet therapy with aspirin and ticlopidine or clopidogrel to prevent acute and subacute thrombosis following coronary artery stenting.
Why the study?
Does clopidogrel improve outcomes compared to ticlopidine in patients receiving coronary artery stents?
Population
Patients receiving coronary artery stents
Comparison
Clopidogrel vs Ticlopidine
Design
Editorial
Authors
Loading...
This editorial discusses the rationale and historical context for transitioning from ticlopidine to clopidogrel as part of dual antiplatelet therapy following coronary stenting.
Does clopidogrel improve outcomes compared to ticlopidine in patients receiving coronary artery stents?
This editorial discusses the rationale and historical context for transitioning from ticlopidine to clopidogrel as part of dual antiplatelet therapy following coronary stenting.
Brookes et al. (1999) conducted an editorial in Coronary stenting. Antiplatelet therapy (ticlopidine, clopidogrel, aspirin) was evaluated. This editorial reviews the rationale for dual antiplatelet therapy with aspirin and ticlopidine or clopidogrel to prevent acute and subacute thrombosis following coronary artery stenting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: